ERBB2 and neoplasm: This first-in-human clinical study showed that IAH0968 was well tolerated with a comparable safety profile and encouraging preliminary anti-tumor activity in participants with metastatic HER2-positive solid tumors who had progressed on at least one prior line of anti-HER2 therapy in the metastatic setting.